Pan-cancer analysis identifies CD155 as a promising target for CAR-T cell therapy
Our study demonstrates that CD155 is selectively expressed in cancer cells while being rarely detected in normal tissues, and may serve as a promising pan-cancer target for CAR-T therapy. Targeting CD155 with CAR-T cells provides an effective approach to treating both solid and hematologic malignancies.
Authors
- Bing Du (ORCID: https://orcid.org/0000-0002-5402-6527)
- Xinyue Lu (ORCID: https://orcid.org/0000-0001-7521-9128)
- Binghe Tan
- Juliang Qin (ORCID: https://orcid.org/0000-0003-3328-3425)
- Hao Xiong (ORCID: https://orcid.org/0000-0003-4862-6689)
- Boxu Lin
- Na Zhang (ORCID: https://orcid.org/0000-0001-9534-0320)
- Chenglin Zhang (ORCID: https://orcid.org/0009-0002-1156-6715)
- Mingyao Liu (ORCID: https://orcid.org/0000-0002-9188-8417)
- Yue Sun (ORCID: https://orcid.org/0000-0003-4261-2382)
- Xiaohong Liu
Institutions
- Shanghai Changzheng Hospital (CN)
- Shanghai Cell Therapy Research Institute (CN)
- East China Normal University (CN)
Publication Details
- Journal
- Genome Medicine
- Published
- 2025-06-02
- DOI
- https://doi.org/10.1186/s13073-025-01490-0
- Citations
- 3
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 3.14
Funders
- Shanghai Municipal Health Commission
- National Natural Science Foundation of China
- Science and Technology Commission of Shanghai Municipality
- East China Normal University
- National Key Research and Development Program of China
- Program of Shanghai Academic Research Leader